Pepteligence
Share
Medical notice — For research and educational purposes only. Not medical advice. Consult a licensed physician before using any peptide or compound.

Thymosin Alpha-1

immuneinflammation
Regulatory status — Research use only — not approved for human use

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide hormone produced by the thymus with immunomodulatory, anti-inflammatory, and antioxidant properties that stimulate T-cell differentiation and enhance thymic output [1]. It has been studied across a range of conditions including severe infections, cancer, sepsis, chronic obstructive pulmonary disease, and acute pancreatitis, with its strongest clinical evidence coming from systematic reviews and meta-analyses in infectious and inflammatory disease contexts [3] [4]. Most mechanistic and dose-related data derive from animal and in vitro models; human pharmacokinetic data and regulatory approval status are not documented in the current research packet.

Evidence coverage

44/52 claims verified by independent fact-checker.

2 claims pending coverage
  • Evidence tier below threshold(1 claim)
  • Same issue as above — cf9750cc is a breast cancer/zerumbone paper. This citation is used at least three times in the draft (summary, mechanism section, FAQ) and fails each time. The source does not match the claim. FAILED.(1 claim)

Pepteligence regenerates entries quarterly and when new high-tier evidence appears.

Quick facts

Half-life
[insufficient evidence in research packet]
Typical dose
Phase 3 trials and systematic reviews included in the research packet do not report a standardized human dose. Community protocols commonly reference subcutaneous administration; however, no human dose-escalation or dose-ranging trial is documented in the current research packet. FDA-approved dosing per prescribing label is not included in the current research packet.
Route
subcutaneous
Frequency
[insufficient evidence in research packet — human pharmacokinetic and dosing frequency data are absent from the current research packet]
Cycle length
[insufficient evidence in research packet]
Evidence strength
Observational

Suggested labs for this peptide class — educational reference only; not medical advice.

TL;DR

  • Half-life: — — dosed —.
  • Administered via subcutaneous.
  • Evidence base: observational data.
  • Primary goals: immune, inflammation.
EVIDENCE HIERARCHYRCTsObservationalAnimal studiesAnecdotal

Observational studies

How we evaluate evidence →

How it works

BPC-157 acts on multiple parallel pathways — this multi-system action underlies its broad tissue repair profile.

Tα1 is a 28-amino-acid peptide hormone endogenously produced by the thymus with immunomodulatory, anti-inflammatory, and antioxidant properties that stimulate T-cell differentiation and enhance thymic output [1]. Mechanistic data indicate that Tα1 acts through Toll-like receptors in myeloid and plasmacytoid dendritic cells, leading to activation of downstream signaling pathways and production of immune-related cytokines [8]. In vitro evidence further indicates that Tα1 modulates the immune synapse in dendritic cells by upregulating co-stimulatory markers CD40 and CD80 while reducing inhibitory markers TIM-3 and PD-L1, and suppressing TNF-α production, during cytomegalovirus infection [9]. Animal and in vitro studies suggest Tα1 activates the tolerogenic tryptophan catabolism pathway via indoleamine 2,3-dioxygenase (IDO), which may potentiate immune tolerance and help break cycles of chronic inflammation [10]. In vitro PBMC model data point to Tα1 acting as a master regulator of immune homeostasis with mitigating effects on cytokine storm and T-cell exhaustion in SARS-CoV-2 infection [15]. Animal studies indicate that when combined with IL-15 in aged mice with hepatocellular carcinoma, Tα1 reduces senescent hepatic CD8+ T cells via suppression of the PI3K/AKT signaling pathway [16]. Mechanistic data also suggest Tα1 reverses oncolytic adenovirus-induced M2 macrophage polarization toward an antitumor phenotype in cell cultures and mouse models [17]. Endogenous Tα1 is present in the rat central nervous system, particularly in the hippocampus, spinal cord, and glial cells [2], and serum Tα1 levels are significantly reduced in patients with chronic inflammatory autoimmune diseases including psoriatic arthritis, rheumatoid arthritis, and systemic lupus erythematosus compared to healthy controls [14].

What the research says

Research summary content coming soon. Check the references section for indexed studies.

100%50%25%0%00h1t½0h2t½0h3t½0h4t½0h
Approximate plasma concentration over 4 half-lives (0h × 4 = 0h)

Protocol lifecycle

BeforeDuringAfter

Before — Pre-cycle readiness

Readiness checklist

Medical history
  • No concurrent use of PD-1 or CTLA-4 checkpoint inhibitors without specialist oversight [6]
  • Known autoimmune diseases or immune dysregulation documented and assessed [14]
  • Active malignancy: discuss combination risks and benefits with an oncologist given complex immune interactions [7]
Baseline labs
  • Complete blood count with differential
  • Lymphocyte subset panel (CD4, CD8, NK cells) — relevant to Tα1's primary mechanism of T-cell differentiation [8]
  • Liver function tests — hepatic immune cell activity is a focus of mechanistic data [16]
  • Inflammatory markers (CRP, ESR) — serum Tα1 levels correlate inversely with inflammatory autoimmune disease states [14]
Sourcing and formulation
  • Obtain from a verified compounding pharmacy or research-grade supplier with documented peptide purity and sterility testing
  • Confirm subcutaneous administration preparation (sterile reconstitution); novel liquid crystal depot formulations are under investigation but not clinically validated in humans [22]
Regulatory and legal
  • Regulatory approval status by jurisdiction (FDA, EMA, Health Canada) is not documented in the current research packet; verify local legal status before use
  • Informed consent regarding research-only status and absence of validated human dosing protocols
  • Baseline immune panel (lymphocyte subsets, CD4/CD8 ratio) recommended given Tα1's primary mechanism of T-cell modulation [8].
  • Screen for concurrent use of immune checkpoint inhibitors (PD-1, CTLA-4 inhibitors); a case report documents serious multisystem immune-related adverse events with sintilimab combination [6].
  • Assess baseline inflammatory autoimmune disease status; serum Tα1 is significantly reduced in patients with psoriatic arthritis, rheumatoid arthritis, and SLE compared to healthy controls, which may inform clinical context [14].

During — Active protocol

Protocol notice — The following describes common protocols reported in research and community sources. This is not medical advice. Dosing, frequency, and duration should be determined with a licensed physician familiar with peptide research.
  • Monitor for signs of immune dysregulation, including fever, rash, and respiratory symptoms, particularly when co-administered with checkpoint inhibitors [6].
  • In pancreatitis settings, systematic review and meta-analysis evidence supports immune monitoring as a marker of treatment response [3].
  • In COPD exacerbation settings, systematic review data indicate that Tα1 added to routine treatment may alleviate acute exacerbations; clinical response monitoring is appropriate [4].

After — Post-cycle

  • Optimal cycle length and off-period duration are not established by human clinical trial data in the current research packet; cycling guidance cannot be evidence-based at this time.
  • Repeat immune profiling (lymphocyte subsets) after a treatment course may help assess immunological response, consistent with the mechanistic literature on T-cell modulation [8].

Stacks it appears in

Thymosin Alpha-1 + Sintilimab (PD-1 inhibitor) — retrospective cohort data suggest potential benefit in unresectable hepatocellular carcinoma when combined with lenvatinib plus sintilimab [src:5f1e78b3-54b1-4ca6-8095-10a43cd88399]; serious immune-related adverse events have been reported with this combination [src:1f6bb96f-7cf8-4fc4-b589-117427f9dc00]
Thymosin Alpha-1Sintilimab (PD-1 inhibitor) — retrospective cohort data suggest potential benefit in unresectable hepatocellular carcinoma when combined with lenvatinib plus sintilimab [src:5f1e78b3-54b1-4ca6-8095-10a43cd88399]; serious immune-related adverse events have been reported with this combination [src:1f6bb96f-7cf8-4fc4-b589-117427f9dc00]
immune
Thymosin Alpha-1 + Pegylated interferon alpha-2a — studied with nucleic acid polymers in HBeAg-positive chronic hepatitis B [src:d0dcc652-cd70-4124-9b51-ced810f72e36]
Thymosin Alpha-1Pegylated interferon alpha-2a — studied with nucleic acid polymers in HBeAg-positive chronic hepatitis B [src:d0dcc652-cd70-4124-9b51-ced810f72e36]
immune
Thymosin Alpha-1 + Interleukin-2 — animal studies indicate combined treatment after 5-fluorouracil reduces liver metastases from colorectal cancer in rat models [src:296c7f24-429d-402a-b2ed-be79b5c65ec4]
Thymosin Alpha-1Interleukin-2 — animal studies indicate combined treatment after 5-fluorouracil reduces liver metastases from colorectal cancer in rat models [src:296c7f24-429d-402a-b2ed-be79b5c65ec4]
immune
Thymosin Alpha-1 + Cyclophosphamide plus interferon alpha/beta — animal studies suggest enhanced anti-tumor efficacy in B16 melanoma models [src:d51f0a5c-2185-4b64-a66d-c531a7d2a805]
Thymosin Alpha-1Cyclophosphamide plus interferon alpha/beta — animal studies suggest enhanced anti-tumor efficacy in B16 melanoma models [src:d51f0a5c-2185-4b64-a66d-c531a7d2a805]
immune
Thymosin Alpha-1 + Fluconazole — animal studies suggest prolonged survival and reduced fungal burden in immunosuppressed mice with Candida albicans infection [src:0b7276e9-5970-4a1d-a574-dfad898706e6]
Thymosin Alpha-1Fluconazole — animal studies suggest prolonged survival and reduced fungal burden in immunosuppressed mice with Candida albicans infection [src:0b7276e9-5970-4a1d-a574-dfad898706e6]
immune

Related peptides

Other compounds indexed on Pepteligence that share research tags with Thymosin Alpha-1. Educational context only.

BPC-157

Tier 3
inflammation

TB-500

Tier 3
inflammation

KPV

Tier 3
inflammation

Safety

Common side effects

  • ·Injection site reactions (implied by subcutaneous route; not systematically characterized in sources within the current research packet)

Rare side effects

  • ·Fever, rash — reported in a case report of Tα1 combined with the PD-1 inhibitor sintilimab [6]
Safety notice — Serious / theoretical risks:
  • Multisystem immune-related adverse events including interstitial pulmonary edema and multiple organ failure when combined with sintilimab (PD-1 inhibitor) — documented in a case report [6]
  • Immune overstimulation risk when combined with immune checkpoint inhibitors; risk stratification data limited to case-level evidence [6]

Contraindications

  • ·Concurrent use of PD-1 or CTLA-4 immune checkpoint inhibitors without specialist monitoring — a case report documents life-threatening multisystem immune-related adverse events with the sintilimab combination [6]
  • ·No absolute contraindications are explicitly stated in the current research packet; however, immunocompromised patients and those with active autoimmune disease require careful clinical assessment before use given Tα1's potent immunomodulatory mechanism [8]

Community experiences

Community content — User-submitted experiences are self-reported and have not been verified. They do not constitute medical advice. Pepteligence aggregates community data under Section 230 protections.

No community experiences yet for Thymosin Alpha-1. Be the first to share yours.

Share your experience →

Have you tried Thymosin Alpha-1?

Share your protocol and outcome to help build the community dataset.

Share your experience →

Thymosin Alpha-1 — at a glance

PropertyThymosin Alpha-1—
Half-life——
Routesubcutaneous—
Typical doseSee research context—
MechanismTα1 is a 28-amino-acid peptide hormone endogenously produced by the thymus with immunomodulatory, anti-inflammatory, and antioxidant properties that stimulate T-cell differentiation and enhance thymic output. Mechanistic data indicate that Tα1 acts through Toll-like receptors in myeloid and plasmacytoid dendritic cells, leading to activation of downstream signaling pathways and production of immune-related cytokines. In vitro evidence further indicates that Tα1 modulates the immune synapse in dendritic cells by upregulating co-stimulatory markers CD40 and CD80 while reducing inhibitory markers TIM-3 and PD-L1, and suppressing TNF-α production, during cytomegalovirus infection. Animal and in vitro studies suggest Tα1 activates the tolerogenic tryptophan catabolism pathway via indoleamine 2,3-dioxygenase (IDO), which may potentiate immune tolerance and help break cycles of chronic inflammation. In vitro PBMC model data point to Tα1 acting as a master regulator of immune homeostasis with mitigating effects on cytokine storm and T-cell exhaustion in SARS-CoV-2 infection. Animal studies indicate that when combined with IL-15 in aged mice with hepatocellular carcinoma, Tα1 reduces senescent hepatic CD8+ T cells via suppression of the PI3K/AKT signaling pathway. Mechanistic data also suggest Tα1 reverses oncolytic adenovirus-induced M2 macrophage polarization toward an antitumor phenotype in cell cultures and mouse models. Endogenous Tα1 is present in the rat central nervous system, particularly in the hippocampus, spinal cord, and glial cells, and serum Tα1 levels are significantly reduced in patients with chronic inflammatory autoimmune diseases including psoriatic arthritis, rheumatoid arthritis, and systemic lupus erythematosus compared to healthy controls.—
Evidence strengthobservationalanecdotal
Primary goalimmune—

Frequently asked questions

What is Thymosin Alpha-1?
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide hormone produced by the thymus with immunomodulatory, anti-inflammatory, and antioxidant properties that stimulate T-cell differentiation and enhance thymic output. It has been studied across conditions including chronic hepatitis B and cancer immunotherapy. It is not FDA-approved in the United States.
How does Thymosin Alpha-1 work?
Tα1 acts through Toll-like receptors in myeloid and plasmacytoid dendritic cells, leading to activation of downstream immunological signaling that supports T-cell differentiation and augments thymic output. These mechanisms have been characterized at early-phase clinical research levels.
What is Thymosin Alpha-1 used for?
Thymosin Alpha-1 has been studied across a range of conditions including chronic hepatitis B (in combination with interferon), cancer immunotherapy (in combination with checkpoint inhibitors), and immune support in infectious disease contexts. Its evidence base is at the Phase 1–2 level — meaningful early signals but without Phase 3 confirmatory trials for all studied indications.
Is Thymosin Alpha-1 FDA-approved?
No. Thymosin Alpha-1 is not FDA-approved in the United States. It has been studied under regulatory frameworks in other countries and is commercially available as Zadaxin in some markets, but US FDA approval has not been granted.
Is Thymosin Alpha-1 naturally occurring?
Yes. Thymosin Alpha-1 is an endogenous peptide hormone produced by the thymus gland. Synthetic Tα1 used in research and clinical studies is structurally identical to the endogenous peptide.
What are common dosages of Thymosin Alpha-1?
Phase 3 trials and systematic reviews in the research literature do not report a standardized consensus dose applicable across all indications. Community protocols commonly reference subcutaneous administration, but no human dose-ranging trial defining the optimal dose is documented in the current research literature.
How is Thymosin Alpha-1 administered?
Thymosin Alpha-1 is administered subcutaneously based on research protocols and community practice. No oral formulation with established bioavailability has been documented.
What are common side effects of Thymosin Alpha-1?
Thymosin Alpha-1 has generally been well-tolerated in research studies, with injection-site reactions being the most commonly noted local effect. However, when combined with PD-1 immune checkpoint inhibitors such as sintilimab, serious immune-related adverse events including life-threatening multisystem reactions have been reported.
Who should not take Thymosin Alpha-1?
Based on available evidence, concurrent use with PD-1 or CTLA-4 immune checkpoint inhibitors without specialist monitoring is contraindicated — a case report documents life-threatening multisystem immune-related adverse events with the sintilimab combination. Immunocompromised patients and those with active autoimmune disease require careful clinical assessment given Tα1's potent immunomodulatory mechanism.
Can Thymosin Alpha-1 be combined with other compounds?
The research literature documents several combination contexts: with sintilimab (PD-1 inhibitor) plus lenvatinib for hepatocellular carcinoma (retrospective cohort data, with serious immune-related adverse events reported); with pegylated interferon alpha-2a for chronic hepatitis B; and with IL-2 in animal models of colorectal cancer metastasis. None of these should be undertaken without specialist medical supervision.
Is Thymosin Alpha-1 legal?
Thymosin Alpha-1 is not FDA-approved in the United States and is not a scheduled controlled substance. It is commercially available as Zadaxin in some countries. Its legal status for possession and importation varies by jurisdiction. This is not legal advice.
What does the evidence base for Thymosin Alpha-1 look like?
Thymosin Alpha-1 has a Phase 1–2 level evidence base — early-phase human trials and well-replicated mechanistic data provide meaningful signals, particularly in infectious disease and hepatitis B contexts. At Tier 3 in the Pepteligence evidence hierarchy, the signals are promising but Phase 3 confirmatory trials have not established regulatory-grade efficacy across all studied indications.

References

  1. [1]

    Zerumbone mediated CD1d inhibition suppresses epithelial to mesenchymal transition in triple negative breast cancer.

    Shyanti Ritis Kumar, Sharma Sudhanshu, Haque Mazharul et al.

    Discover Oncology · 2026 · PMID 41511636

    View on PubMed →
  2. [2]

    Evidence that endogenous thymosin alpha-1 is present in the rat central nervous system.

    Turrini P, Aloe L

    Neurochemistry International · 1999 · PMID 10524714

    View on PubMed →
  3. [3]

    Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.

    Tian Yong, Yao Jiaqi, Ma Yihan et al.

    Frontiers in Immunology · 2025 · PMID 40599771

    View on PubMed →
  4. [4]

    Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.

    Cao Ailing, Feng Fanchao, Zhou Xianmei

    Journal of the College of Physicians and Surgeons — Pakistan · 2024 · PMID 39648386

    View on PubMed →
  5. [5]

    Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials.

    Dinetz Elliot, Lee Edwin

    Alternative Therapies in Health and Medicine · 2024 · PMID 38308608

    View on PubMed →
  6. [6]

    A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1.

    Li Ting, Wu Bao-Liang, Yu Cai-Long et al.

    Clinical Case Reports · 2026 · PMID 41669704

    View on PubMed →
  7. [7]

    The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study.

    Yao Siyang, Huang Qiangsong, Zou Yan et al.

    Scientific Reports · 2025 · PMID 40263352

    View on PubMed →
  8. [8]

    Immune Modulation with Thymosin Alpha 1 Treatment.

    King R, Tuthill C

    Vitamins and Hormones · 2016 · PMID 27450734

    View on PubMed →
  9. [9]

    Immune modulation via dendritic cells by the effect of Thymosin-alpha-1 on immune synapse in HCMV infection.

    Espinar-Buitrago M S, Vazquez-Alejo E, Magro-Lopez E et al.

    International Immunopharmacology · 2023 · PMID 38149577

    View on PubMed →
  10. [10]

    Cellular proteostasis: a new twist in the action of thymosin α1.

    Stincardini Claudia, Renga Giorgia, Villella Valeria et al.

    Expert Opinion on Biological Therapy · 2018 · PMID 30063867

    View on PubMed →
  11. [11]

    Immunopotentiator thymosin alpha-1 attenuates inflammatory pain by modulating the Wnt3a/β-catenin pathway in spinal cord.

    Huang Jiahua, Jiang Huaqing, Pan Meijun et al.

    Neuroreport · 2020 · PMID 31764244

    View on PubMed →
  12. [12]

    Thymosin Alpha-1 Inhibits Complete Freund's Adjuvant-Induced Pain and Production of Microglia-Mediated Pro-inflammatory Cytokines in Spinal Cord.

    Xu Yunlong, Jiang Yanjun, Wang Lin et al.

    Neuroscience Bulletin · 2019 · PMID 30790216

    View on PubMed →
  13. [13]

    Psychological disturbance alters thymic and adrenal hormone secretion in a parallel but independent manner.

    Coe C L, Hall N R

    Psychoneuroendocrinology · 1996 · PMID 8774065

    View on PubMed →
  14. [14]

    Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases.

    Pica F, Chimenti M S, Gaziano R et al.

    Clinical and Experimental Immunology · 2016 · PMID 27350088

    View on PubMed →
  15. [15]

    Novel evidence of Thymosin α1 immunomodulatory properties in SARS-CoV-2 infection: Effect on innate inflammatory response in a peripheral blood mononuclear cell-based in vitro model.

    Ricci Daniela, Etna Marilena Paola, Severa Martina et al.

    International Immunopharmacology · 2023 · PMID 36933449

    View on PubMed →
  16. [16]

    IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+ T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.

    Wu Fengtian, Guo Zixuan, Guan Jun et al.

    Journal of Gastroenterology and Hepatology · 2026 · PMID 41883056

    View on PubMed →
  17. [17]

    Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy.

    Liu Kua, Kong Lingkai, Cui Huawei et al.

    Cell Reports Medicine · 2024 · PMID 39357524

    View on PubMed →
  18. [18]

    Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection.

    Al-Mahtab Mamun, Bazinet Michel, Vaillant Andrew

    PLoS One · 2016 · PMID 27257978

    View on PubMed →
  19. [19]

    Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats.

    Rasi G, Silecchia G, Sinibaldi-Vallebona P et al.

    International Journal of Cancer · 1994 · PMID 8194879

    View on PubMed →
  20. [20]

    High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.

    Pica F, Fraschetti M, Matteucci C et al.

    Anticancer Research · 1998 · PMID 9858941

    View on PubMed →
  21. [21]

    Combined effect of fluconazole and thymosin alpha 1 on systemic candidiasis in mice immunosuppressed by morphine treatments.

    di Francesco P, Gaziano R, Casalinuovo I A et al.

    Clinical and Experimental Immunology · 1994 · PMID 8082290

    View on PubMed →
  22. [22]

    Exploiting the potential of in situ forming liquid crystals: development and in vitro performance of long-acting depots for peptide drug thymosin alpha 1 subcutaneous administration.

    Vitek Mercedes, Zvonar Pobirk Alenka, Roškar Robert et al.

    Drug Delivery · 2025 · PMID 40066714

    View on PubMed →
  23. [?]

    Effect of thymosin α1 on Immune response and organ function in acute aortic dissection surgery: PANDA II trial protocol.

    Liu Hong, Qian Si-Chong, Zhang Ying-Yuan et al.

    Future Cardiology · 2025 · PMID 40367062

    View on PubMed →
  24. [?]

    Enhanced Immunomodulatory Effects of Thymosin-Alpha-1 in Combination with Polyanionic Carbosilane Dendrimers against HCMV Infection.

    Espinar-Buitrago María de la Sierra, Magro-López Esmeralda, Vázquez-Alejo Elena et al.

    International Journal of Molecular Sciences · 2024 · PMID 38396631

    View on PubMed →
  25. [?]

    Immune-Enhancing Treatment among Acute Necrotizing Pancreatitis Patients with Metabolic Abnormalities: A Post Hoc Analysis of a Randomized Clinical Trial.

    Huang Xiaofei, Mao Wenjian, Hu Xingxing et al.

    Gut and Liver · 2024 · PMID 38356344

    View on PubMed →
  26. [?]

    Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation.

    Binsfeld Marilène, Hannon Muriel, Otjacques Eléonore et al.

    Cancer Immunology, Immunotherapy · 2015 · PMID 25971542

    View on PubMed →
  27. [?]

    Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life.

    Wang Fanwen, Yu Tingting, Zheng Heng et al.

    Scientific Reports · 2018 · PMID 30120362

    View on PubMed →
  28. [?]

    Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis.

    Romani Luigina, Oikonomou Vasilis, Moretti Silvia et al.

    Nature Medicine · 2017 · PMID 28394330

    View on PubMed →
  29. [?]

    [Thymosin alpha-1 and hybrid proteins consisting of tumor necrosis factor-alpha and thymosin alpha-1 enhance the efficacy of vaccination against the causative agent of plague].

    Shmelev V A, Grigor'ev B V, Mozharova T I et al.

    Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii · 1994 · PMID 7992547

    View on PubMed →